You are a helpful, respectful, and honest assistant. Always answer as helpfully as possible, while being safe. Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content. Please ensure that your responses are socially unbiased and positive in nature. If a question does not make any sense or is not factually coherent, explain why instead of answering something not correct. If you don't know the answer to a question, please don't share false information.
What is What is true about HER2/neu overexpression in Ca breast and explain in detail?
.* Tumour grade, growth factor and oncogene factors. ErbB2 -Her-2/neu positive has got poor prognosis. ErbB1 with over expression of epidermal growth factor (EGF), TGF alpha and cathepsin D has got poor prognosis. * Progesterone receptor (PR status) study or Her 2 Neu receptor status or cErb B2 (growth factor receptor study) are other studies done at present to plan the therapy and assess the prognosis. TRANSTUZUMAB (Herceptin)- * It is a monoclonal antibody that blocks HER-2/neu receptors thereby preventing growth of cancer cells. It is a new drug. It is presently marketed as herceptin. It is c-ErbB2 (growth factor receptor) inhibitor. It is a newer biological agent. * It has very little effect on HER-2/neu negative cancers. * It is useful only in HER-2/neu positive cancers. It is currently approved by FDA for use only in metastatic disease. It is given as intravenous infusion. ref:SRB&;s manual of surgery,ed 3,pg no 486